Base4 and Hitachi High-Tech Collaborate on Developing Novel Nanopore DNA-Sequencing System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Base4 and Hitachi High-Tech Collaborate on Developing Novel Nanopore DNA-Sequencing System
The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so.


Base4 Innovation Ltd., a Cambridge-based DNA-sequencing company, and Hitachi High-Technologies Corporation, a technology company developing and manufacturing scientific and medical systems, announced that they have entered into an agreement to develop a long read-length, single-molecule, nanopore-based DNA-sequencing system based on Base4’s technology and Hitachi’s state-of-the-art instrumentation.

The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so. A method was developed by Base4 to increase the signal from the single molecule as it passes through the pore by using laser light enhanced by gold structures. Minimal sample preparation is required and the signal can be read from unlabelled DNA.

The system offers easy analysis of genetic material. It will be able to directly read DNA modifications, such as methylation, which is relevant to the genes associated with cancer, as well as achieve long read lengths.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here